FI104790B - Menetelmä aktivoidun proteiini C:n valmistamiseksi - Google Patents

Menetelmä aktivoidun proteiini C:n valmistamiseksi Download PDF

Info

Publication number
FI104790B
FI104790B FI885331A FI885331A FI104790B FI 104790 B FI104790 B FI 104790B FI 885331 A FI885331 A FI 885331A FI 885331 A FI885331 A FI 885331A FI 104790 B FI104790 B FI 104790B
Authority
FI
Finland
Prior art keywords
protein
apc
purified
activated protein
dose
Prior art date
Application number
FI885331A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI885331A (fi
FI885331A0 (fi
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104790(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI885331A0 publication Critical patent/FI885331A0/fi
Publication of FI885331A publication Critical patent/FI885331A/fi
Application granted granted Critical
Publication of FI104790B publication Critical patent/FI104790B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI885331A 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi FI104790B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism
US12170287 1987-11-17

Publications (3)

Publication Number Publication Date
FI885331A0 FI885331A0 (fi) 1988-11-17
FI885331A FI885331A (fi) 1989-05-18
FI104790B true FI104790B (fi) 2000-04-14

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885331A FI104790B (fi) 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi

Country Status (11)

Country Link
US (2) US5084274A (ja)
EP (1) EP0318201B1 (ja)
JP (1) JP2766986B2 (ja)
AT (1) ATE135234T1 (ja)
CA (1) CA1330036C (ja)
DE (1) DE3855096T2 (ja)
DK (1) DK175704B1 (ja)
ES (1) ES2086301T3 (ja)
FI (1) FI104790B (ja)
GR (1) GR3020036T3 (ja)
NO (1) NO301747B1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
EP0709096A2 (de) * 1991-04-16 1996-05-01 Roche Diagnostics GmbH Pharmazeutische Verpackungseinheit enthaltend Plasminogenaktivatoren zur Mehrfachbolusgabe
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US6143719A (en) * 1995-06-09 2000-11-07 The Regents Of The University Of Michigan Bradykinin analogs as selective thrombin inhibitors
PL335802A1 (en) * 1997-03-24 2000-05-22 Lilly Co Eli Method of treating vascular disorders
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DK1133314T3 (da) 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
DE60144366D1 (de) 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20040122354A1 (en) * 2002-09-05 2004-06-24 Semba Charles P. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
MX2007010359A (es) 2005-02-24 2008-04-04 Diffusion Pharmaceuticals Llc Trans carotenoides, su sintesis, formulacion y usos.
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
EP2078074A4 (en) * 2006-10-31 2011-09-28 Scripps Research Inst DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY
WO2008136900A1 (en) 2007-04-13 2008-11-13 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US10130689B2 (en) * 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
US11185523B2 (en) 2016-03-24 2021-11-30 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
EP0215548B2 (en) * 1985-06-27 1998-01-07 Zymogenetics, Inc. Expression of protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
NO885109L (no) 1989-05-18
EP0318201A3 (en) 1990-02-07
GR3020036T3 (en) 1996-08-31
DE3855096T2 (de) 1996-07-25
DE3855096D1 (de) 1996-04-18
ES2086301T3 (es) 1996-07-01
ATE135234T1 (de) 1996-03-15
EP0318201A2 (en) 1989-05-31
EP0318201B1 (en) 1996-03-13
FI885331A (fi) 1989-05-18
NO301747B1 (no) 1997-12-08
DK175704B1 (da) 2005-01-24
JP2766986B2 (ja) 1998-06-18
NO885109D0 (no) 1988-11-16
US5350578A (en) 1994-09-27
DK640088A (da) 1989-05-18
JPH01238536A (ja) 1989-09-22
FI885331A0 (fi) 1988-11-17
CA1330036C (en) 1994-06-07
US5084274A (en) 1992-01-28
DK640088D0 (da) 1988-11-16

Similar Documents

Publication Publication Date Title
FI104790B (fi) Menetelmä aktivoidun proteiini C:n valmistamiseksi
US6037322A (en) Methods for treating vascular disorders using activated protein C
US6071514A (en) Methods for treating thrombotic disorders
JP2506521B2 (ja) Ｌｙｓ−プラスミノ―ゲンを含有する医薬
WO1999049880A1 (en) Methods for treating an ischemic disorder and improving stroke outcome
AU7185600A (en) A pharmaceutical preparation for treating blood coagulation disorders
JPH08510746A (ja) 改良型▲ｖｉｉ▼因子
JP2009137983A (ja) 発作を処置するための非神経毒性プラスミノゲンを活性化する因子
WO2004093797A2 (en) Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
JP5236952B2 (ja) 改善された特性を有するｆｘｉｉｉバリアント
WO1993009807A1 (en) Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
EP0872245B1 (en) Methods for treating vascular disorders with activated Protein C
EP1067879B1 (en) Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
EP1128842B1 (en) Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
JP2003514545A (ja) プロテインｃ誘導体
Douglas Fibrinolytic agents
UA48149C2 (uk) Спосіб інгібування активності фактора тканини, спосіб пригнічення відкладення тромбоцитів, спосіб пригнічення судинного рестенозу, спосіб лікування гострої закупорки коронарної артерії за допомогою модифікованого фактора vii
CZ338799A3 (cs) Terapeutický přípravek, nádržka s dávkovou jednotkou tohoto přípravku a aktivovaný protein C
MXPA01005038A (en) Method of treating viral hemorrhagic fever

Legal Events

Date Code Title Description
FG Patent granted

Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION

MA Patent expired